Scholarlink

<p>Osimertinib has been one of the most commonly prescribed first-line treatments for EGFR-mutated advanced NSCLC for the last several years for patients with EGFR-mutated non-small cell lung cancer (NSCLC), yet clinical outcomes among racial and ethnic minority patients remain poorly characterized due to underrepresentation in pivotal trials. We conducted a retrospective study of 174 patients with advanced EGFR-mutated NSCLC treated at the Montefiore Einstein Comprehensive Cancer Center (MECCC) from 2015 to 2024 to evaluate real-world survival and treatment adherence. The cohort included 32.2% Hispanic, 28.7% non-Hispanic Black (NHB), 26.4% non-Hispanic White (NHW), and 12.6% Asian patients. In multivariable analyses, NHB patients experienced significantly worse overall survival compared with NHW patients, both in the overall cohort (Hazard ratio (HR) 1.83, 95% confidence interval (CI) 1.02–3.27) and in first-line osimertinib users (HR 3.42, 95% CI 1.48–7.88), despite similar adherence rates. Hispanic and Asian patients also showed trends toward inferior outcomes. These findings highlight survival disparities and underscore the need for inclusive trials and targeted strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Matthew Lee,
  • Junmin Song,
  • Emily Miao,
  • Daniel S. Alicea,
  • Chenxin Zhang,
  • Xiaonan Xue,
  • Steven Tuckman,
  • Jihua Yang,
  • Angelica D’Aiello,
  • Rasim Gucalp,
  • Brendon Stiles,
  • Nitin Ohri,
  • Balazs Halmos,
  • Haiying Cheng

摘要

Osimertinib has been one of the most commonly prescribed first-line treatments for EGFR-mutated advanced NSCLC for the last several years for patients with EGFR-mutated non-small cell lung cancer (NSCLC), yet clinical outcomes among racial and ethnic minority patients remain poorly characterized due to underrepresentation in pivotal trials. We conducted a retrospective study of 174 patients with advanced EGFR-mutated NSCLC treated at the Montefiore Einstein Comprehensive Cancer Center (MECCC) from 2015 to 2024 to evaluate real-world survival and treatment adherence. The cohort included 32.2% Hispanic, 28.7% non-Hispanic Black (NHB), 26.4% non-Hispanic White (NHW), and 12.6% Asian patients. In multivariable analyses, NHB patients experienced significantly worse overall survival compared with NHW patients, both in the overall cohort (Hazard ratio (HR) 1.83, 95% confidence interval (CI) 1.02–3.27) and in first-line osimertinib users (HR 3.42, 95% CI 1.48–7.88), despite similar adherence rates. Hispanic and Asian patients also showed trends toward inferior outcomes. These findings highlight survival disparities and underscore the need for inclusive trials and targeted strategies.